Sanofi’s Easier to Use Hemophilia Drug Approved by US FDA
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...
Fierce Pharma17h
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
BioPharma Dive13h
FDA approves first-of-its-kind RNA drug for hemophilia
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
Sanofi Agrees US Autoimmune Drug Deal for Up to $1.9 Billion
Sanofi is buying an immunology drug from Dren Bio, Inc. for up to $1.9 billion, in a deal it said will help it become a ...
EconoTimes5h
Sanofi’s New Hemophilia Drug Qfitlia Gains FDA Approval with Breakthrough Bimonthly Dosing
The U.S. Food and Drug Administration (FDA) has approved Qfitlia, a groundbreaking hemophilia treatment by French pharmaceutical giant Sanofi (NASDAQ: SNY). Designed for patients aged 12 and older ...
FDA approves Sanofi treatment for hemophilia A or B
The U.S. Food and Drug Administration approved Qfitlia for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult ...
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...
MedCity News8d
Sanofi Expands Immunology Prospects, Acquiring Novel Bispecific Drug in $600M Deal
Sanofi is adding a new contender, agreeing to pay $600 million for a bispecific drug with an approach that could be first in class. The sum announced Thursday is an upfront payment for Dren Bio ...
Medical Dialogues6h
USFDA approves Sanofi Qfitlia for hemophilia A or B with or without inhibitors
Paris: Sanofi has announced that the Company has received approval from the US Food and Drug Administration (FDA) for Qfitlia ...
Sanofi: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent prot ...
GlobalData on MSN3d
FDA fast tracks Sanofi’s mRNA vaccine for chlamydia
Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.